Senate Files

Bills

S. 2305 118th Congress

Biosimilar Red Tape Elimination Act

Latest action, Jul 13, 2023: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

4 cosponsors

Sponsored by Mike Lee (Republican). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
1 D · 3 R
  • Democrat
  • Republican
  • Independent
4 senators cosponsoring

Referred to: Senate: Health, Education, Labor, and Pensions Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

32 clientsQ3 2023Q4 2024

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

AMGEN INC
6 reports
BCBSM INC
6 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
6 reports
GSK (FKA GLAXOSMITHKLINE INC.)
6 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
6 reports
THE BIOSIMILARS FORUM
THORN RUN PARTNERS
6 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
5 reports
BLUE CROSS AND BLUE SHIELD ASSOCIATION
5 reports
CAMBIA HEALTH SOLUTIONS
5 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
5 reports
ELEVANCE HEALTH, INC.
5 reports
JOHNSON & JOHNSON SERVICES INC
5 reports
TEVA PHARMACEUTICALS USA INC
5 reports
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
4 reports
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC
4 reports
All 25 of 42 clients
ClientLobbying firmReportsReports totalingFromToSenate
AMGEN INC6$18.1MQ4 2023Q3 2024yes
BCBSM INC6$176KQ4 2023Q3 2024yes
BIOTECHNOLOGY INNOVATION ORGANIZATION6$11.1MQ4 2023Q3 2024yes
GSK (FKA GLAXOSMITHKLINE INC.)6$7.3MQ4 2023Q3 2024yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA6$43.8MQ4 2023Q3 2024yes
THE BIOSIMILARS FORUMTHORN RUN PARTNERS6$620KQ4 2023Q3 2024yes
ASSOCIATION FOR ACCESSIBLE MEDICINES5$3.0MQ4 2023Q3 2024yes
BLUE CROSS AND BLUE SHIELD ASSOCIATION5$8.7MQ3 2023Q3 2024yes
CAMBIA HEALTH SOLUTIONS5$3.2MQ4 2023Q3 2024yes
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)WHITMER & WORRALL, LLC5$120KQ4 2023Q3 2024yes
ELEVANCE HEALTH, INC.5$7.6MQ4 2023Q3 2024yes
JOHNSON & JOHNSON SERVICES INC5$8.9MQ4 2023Q3 2024yes
TEVA PHARMACEUTICALS USA INC5$2.5MQ4 2023Q3 2024yes
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS4$920KQ1 2024Q3 2024yes
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC4$650KQ4 2023Q2 2024yes
GUIDEWELL MUTUAL HOLDING CORPORATION4$30KQ4 2023Q2 2024yes
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCCOVINGTON & BURLING LLP4$0Q1 2024Q3 2024yes
PRIME THERAPEUTICS4$370KQ3 2023Q3 2024yes
AMERICANS FOR PROSPERITY3$1.4MQ4 2023Q1 2024yes
GOVERNMENT COUNSEL, LLC (OBO) PRIME THERAPEUTICSHOOPER, LUNDY & BOOKMAN, P.C.3$30KQ3 2023Q4 2024yes
TAKEDA PHARMACEUTICALS AMERICA INC3$2.4MQ4 2024Q3 2024yes
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.3$180KQ4 2024Q3 2024yes
AMNEAL PHARMACEUTICALS2$440KQ4 2024Q3 2024yes
BLUE CROSS AND BLUE SHIELD OF KANSAS INC2$15KQ3 2023Q4 2024yes
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION2$690KQ4 2023Q3 2023yes